drugset

drugset / Trial / NCT05927779

Study of TFX06 in Women With Advanced Breast Cancer.

NCT05927779 ↗

Phase 1/2 Unknown 74 enrolled Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

NaSequentialOpen-labelTreatment

Summary

A Phase 1/2 Dose Escalation and Expansion Study of TFX06 tablet Alone in Women with ER Positive, HER2 Negative Advanced Breast Cancer

Timeline

Start: 2023-04-17
Primary completion: 2024-12-30
Completion: 2025-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TFX06	Unknown	—	Oral

Indications